Tyme Technologies (TYME) Completes Strategic Review, Announces OASIS Breast Trial With Georgetown University, and Reports FY21 Financial Results

Tyme Technologies, Inc. Completes Strategic Review, Announces OASIS Breast Trial With Georgetown University, and Reports Fiscal Year 2021 Financial Results

Comprehensive strategic review identified breast cancer as a priority indication for development, a focus on second-line pancreatic cancer, and continuation of trial in high-risk sarcomas

Recently appointed acting Chief Medical Officer and incoming Chief Financial Officer bolster leadership team expertise

Well-capitalized position, with $107.5 million in cash as of Q4 FY2021

Company to host live conference call and video webcast today, June 10, 2021, at 5:00 PM ET

BEDMINSTER, N.J.--(BUSINESS WIRE)-- Tyme Technologies, Inc. (Nasdaq: TYME) (the Company or TYME), an emerging biotechnology company... More